Vantictumab

CAS No. 1345009-45-1

Vantictumab( —— )

Catalog No. M36901 CAS No. 1345009-45-1

Vantictumab (OMP-18R5) is a humanized anti-FZD1/2/5/7/8 monoclonal antibody that inhibits Wnt pathway signaling and is used in research studies for the treatment of metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 375 Get Quote
5MG 613 Get Quote
10MG 938 Get Quote
25MG 1408 Get Quote
50MG 1822 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Vantictumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Vantictumab (OMP-18R5) is a humanized anti-FZD1/2/5/7/8 monoclonal antibody that inhibits Wnt pathway signaling and is used in research studies for the treatment of metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma.
  • Description
    Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab is being studied against cancers such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Wnt/Notch/Hedgehog
  • Target
    Wnt/beta/catenin
  • Recptor
    Wnt/beta-catenin
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1345009-45-1
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Davis SL, et al. A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer. Invest New Drugs. 2020 Jun;38(3):821-830.?
molnova catalog
related products
  • ABC99

    ABC99 is a selective irreversible inhibitor of the wnt-deacylating enzyme. ABC99 inhibited NOTUM (IC50: 13 nM). It also showed excellent selectivity across the serine hydrolase family.

  • TNIK-IN-5

    TNIK-IN-5 is an inhibitor of TNIK and can be used in studies about the treatment of anti-tumor and anti-inflammatory diseases.

  • EMT inhibitor-1

    EMT inhibitor -1 is an inhibitor of Hippo, Wnt signaling and TGF- macrophages (TGF-) with antitumor activity.